Canine BNP antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Canine BNP antibodies pairs and antigen for animal health (animal Dog/Canine Cardiovascular Disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-CAN-BNP-Ag01	Canine BNP	$3090.00
GMP-CAN-BNP-Ab01	Anti-Canine BNP mouse monoclonal antibody (mAb)	$3090.00
GMP-CAN-BNP-Ab02	Anti-Canine BNP mouse monoclonal antibody (mAb)	$3090.00
GMP-CAN-BNP-Ab03	Anti-Canine BNP human monoclonal antibody (mAb)	$3090.00
GMP-CAN-BNP-Ab04	Anti-Canine BNP human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-CAN-BNP-Ag01
Product Name	Canine BNP
Target/Biomarker	Canine BNP
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Canine BNP antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in BNP level test of animal Dog/Canine with Cardiovascular Disease.
Tag	His
Reconized/Reactive Specics	Canine BNP
Product description	Recombinant Canine BNP protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-CAN-BNP-Ab01,GMP-CAN-BNP-Ab02
Target/Biomarker	Canine BNP
Product Name	Anti-Canine BNP mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Canine BNP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine BNP antibodies in Canine BNP level test of animal Dog/Canine with Cardiovascular Disease.
Product description	Anti-Canine BNP mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine BNP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-CAN-BNP-Ab03,GMP-CAN-BNP-Ab04
Target/Biomarker	Canine BNP
Product Name	Anti-Canine BNP human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Canine BNP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine BNP antibodies in Canine BNP level test of animal Dog/Canine with Cardiovascular Disease.
Product description	Anti-Canine BNP mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Diseases Detected by NT-proBNP: Insights into Veterinary Cardiology

This table outlines how NT-proBNP levels correlate with heart disease across various animals, detailing normal ranges, disease implications, and measurement methods.

NT-proBNP Biomarker and Its Implications in Veterinary Diseases

Animals	Normal Range	Possible Diseases Listed (Detail)	Specimens/Biofluids	Measurement Method
Cat	<100 pmol/L	HCM (Hypertrophic Cardiomyopathy);RCM (Restrictive Cardiomyopathy); DCM (Dilated Cardiomyopathy) ; Congestive Heart Failure;Arterial Thromboembolism; Systemic Hypertension	Blood Plasma/Serum	ELISA, Chemiluminescence
Dog	<900 pmol/L	DCM; Valvular Heart Disease;Congestive Heart Failure;Chronic Valvular Disease;Pulmonary Hypertension;Cardiac Arrhythmias	Blood Plasma/Serum	ELISA, Chemiluminescence
Horse	-	Atrial Fibrillation; Equine Metabolic Syndrome-related cardiac changes;Congestive Heart Failure	Blood Plasma/Serum	ELISA, Chemiluminescence
Cattle	-	Limited data available, but potential use in detecting heart failure or stress due to metabolic syndromes in dairy cows	Blood Plasma/Serum	ELISA, Chemiluminescence

Note:

"HCM" stands for Hypertrophic Cardiomyopathy, a common heart disease in cats characterized by thickened heart walls."DCM" is Dilated Cardiomyopathy, observed in dogs, characterized by an enlarged heart with poor contraction.The "Normal Range" values provided are generalized; specific values can vary based on the testing method, equipment used, and individual patient factors. It's important to consult veterinary diagnostic reference materials or laboratories for precise normal ranges.In cases where data is not available ("-"), it indicates that the use of NT-proBNP for those specific animals or diseases is either not common or not well-documented in available literature.

Canine quantitative immunoassay reagent for NT-proBNPF

GeneMedi has created many monoclonal antibodies against canine NT-proBNP. All antibodies were examined as capture and detection antibodies in a sandwich immunoassay to find the best antibody pairing. 96-well plates are coated with capture antibodies, and europium chelates mark detection antibodies. To assess antibody pairings, two types of canine NT-proBNP were utilized as antigens: natural canine NT-proBNP from dog plasma and recombinant canine NT-proBNP (Cat. # GMP-CAN-NT-proBNP-Ag01). High sensitivity was demonstrated by many pairings in identifying native and recombinant NT-proBNP. Table 1 displays the best monoclonal antibody pairs.

 

Capture antibody	Detect antibodies
GMP-CAN-NT-proBNP-Ab01	GMP-CAN-NT-proBNP-Ab02
GMP-CAN-NT-proBNP-Ab05	GMP-CAN-NT-proBNP-Ab02
GMP-CAN-NT-proBNP-Ab01	GMP-CAN-NT-proBNP-Ab06

Table 1. Most sensitive antibody pairs

 

These immunoassays have a sensitivity of 22 pg/mL for measuring recombinant NT-proBNP. Figures 1 and 2 display the suggested pairing calibration curves.  Conversion of 1NT-proBNP concentration: 1 pmol/L = 1÷10.545 pg/ml Please note that a variety of factors might affect how well an immunoassay test performs. These consist of the labeling procedure, the kind of label coupled to the detection antibody, and the detection platform. Thus, on our customers' immunoassay systems, other NT-proBNP antibody pairs with non-overlapping epitopes could perform better.

Figure 1, 2. NT-proBNP immunoassay calibration curve

(A) Calibration curve for optimal paired detection

(B) Calibration curve and canine plasma sample dilution comparison

Reagent type: two-step sandwich immunofluorescence detection, streptavidin-coated microplate

Capture antibody: 200ng/well, conjugated biotin

Capture antibody: 200ng/well, labeled europium chelate

Antigen: Canine recombinant NT-proBNP (Cat.#GMP-CAN-NT-proBNP-Ag01)

Sample volume: 50μl

Incubation time: 40 minutes at room temperature

Quantitative detection of NT-proBNP in plasma of healthy dogs and dogs with heart disease

These immunoassays have a sensitivity of 22 pg/ml 1 for measuring recombinant NT-proBNP. Figures 1 and 2 display the suggested pairing calibration curves. Conversion of 1 NT-proBNP concentration: 1 pmol/L = 1÷10.545 pg/ml Please be aware that a variety of factors might affect how well an immunoassay test performs. These consist of the labeling procedure, the kind of label coupled to the detection antibody, and the detection platform. Thus, on our customers' immunoassay systems, other NT-proBNP antibody pairs with non-overlapping epitopes could perform better.

Figure 3. NT-proBNP concentration in EDTA plasma samples from healthy dogs and dogs with heart disease.

Reagent type: two-step sandwich immunofluorescence detection, streptavidin-coated microplate

Capture antibody: GMP-CAN-NT-proBNP-Ab01, 1μg/well

Capture antibody: GMP-CAN-NT-proBNP-Ab02, 200ng/well, labeled europium chelate

Calibrator: Canine recombinant NT-proBNP (Cat.# GMP-CAN-NT-proBNP-Ag01)

Sample volume: 50μl

Incubation time: 40 minutes at room temperature

Improved apparent stability of endogenous NT-proBNP in plasma samples

The gradual breakdown of proteins over time poses a challenge in accurately measuring NT-proBNP content in samples (5-7). Proper sample handling and storage are crucial, but selecting antibodies for detection reagents is equally important. Immunoreactivity decreases if an epitope in either the capture or detection antibodies is broken or located at a protease cleavage point. Therefore, using antibodies that precisely target the stabilizing region can enhance analyte stability. In developing canine NT-proBNP detection reagents, it's vital to choose antibodies resistant to proteolytic degradation of NT-proBNP.

Our antibodies were tested for their ability to detect endogenous canine NT-proBNP during sample storage. EDTA plasma from dogs with heart disease was incubated at two temperatures: +4°C and +20°C. At +4°C, NT-proBNP remains stable for at least 72 hours (95–105% of initial immunoreactivity, Figure 4A). Simultaneously, at +20°C, about 98% of the initial immunoreactivity is detectable after 24 hours (Figure 4B). Using our recommended antibody pairings, plasma can be stored at +4°C for at least 72 hours with minimal loss of immunoreactivity. However, at room temperature, there is a slight weakening of the signal during the first 24 hours. Note that individual plasma or serum samples may vary.

Figure 4 , 5. Stability of endogenous canine NT-proBNP in EDTA plasma

(A) Immunoreactivity of NT-proBNP in plasma samples incubated for 24, 48 and 72 hours at +4°C.

(B) Immunoreactivity of NT-proBNP in plasma samples incubated for 4, 8, 24 and 48 hours at +20°C. Collect protease inhibitor-free EDTA plasma; samples are centrifuged, separated, and stored at -70°C before use. EDTA plasma is stored at +4°C or +20°C with the addition of 0.1% NaN3 to prevent bacterial growth. After incubation, samples were stored at -70°C before measurement. The NT-proBNP concentration in plasma was 9 ng/ml (determined by GMP-CAN-NT-proBNP-Ab01 and GMP-CAN-NT-proBNP-Ab02 immunoassays). Detection using GMP-CAN-NT-proBNP-Ab01 and GMP-CAN-NT-proBNP-Ab05 as capture antibodies and GMP-CAN-NT-proBNP-Ab06 and GMP-CAN-NT-proBNP-Ab02 as detection antibodies respectively The system results are depicted in Figure 3.

Click to get more Data / Case study about the product.

Target/Biomarker Information

Canine B-type Natriuretic Peptide, or Canine BNP, stands as a remarkable biomarker in the intricate orchestra of canine cardiovascular health. Synthesized primarily within the ventricles of the heart in domestic dogs (Canis lupus familiaris), BNP is a member of the natriuretic peptide family, joining forces with atrial natriuretic peptide (ANP) to orchestrate blood pressure and fluid balance in the canine body.

The production and release of Canine BNP are intricately regulated processes. When the heart faces increased pressure or volume overload, often resulting from conditions like congestive heart failure (CHF), valvular disease, or cardiomyopathy, the ventricles respond by liberating BNP into the bloodstream. This natural response aims to mitigate the strain on the heart and enhance cardiovascular stability.

Canine BNP, upon release, initiates a chain of events by binding to specific receptors in the kidneys and blood vessels. This binding event triggers a cascade that culminates in increased sodium and water excretion by the kidneys. By promoting diuresis, BNP contributes to the reduction of blood volume and a decrease in cardiac workload.

The significance of Canine BNP goes beyond its role as a simple hormonal regulator. It serves as a sentinel, a messenger that heralds changes within the canine cardiovascular system. Elevated Canine BNP levels signal the presence of cardiac challenges, often before clinical symptoms manifest. As a result, Canine BNP is a powerful diagnostic tool, allowing veterinarians to detect heart-related issues early and intervene promptly.

About GDU